Abstract
Numerous clinical trials indicate that the APOE µ4 allele is the genetic marker that exhibits a more consistent association with late onset Alzheimer's disease (AD) and it is considered an increased risk factor for the development of AD in up to 4 times. Evidence for its negative impact on brain activity has been demonstrated by electroencephalograms such as event related potential (ERPs)…